Analyst Reco. Theravance Biopharma, Inc.

Equities

TBPH

KYG8807B1068

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
9.12 ^USD	-0.22%		-2.36%	-18.86%

12/04	Sector Update: Health Care Stocks Lower Friday Afternoon	MT
12/04	Theravance Biopharma Shares Rise After BTIG Starts Coverage at Buy	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Theravance Biopharma Shares Rise After BTIG Starts Coverage at Buy	12/04	MT
BTIG Starts Theravance Biopharma With Buy Rating, $21 Price Target	12/04	MT
HC Wainwright Adjusts Price Target on Theravance Biopharma to $20 From $19, Keeps Buy Rating	09/23/09	MT
SVB Securities Adjusts Price Target on Theravance Biopharma to $14 From $12, Maintains Outperform Rating	17/22/17	MT
HC Wainwright Adjusts Price Target on Theravance Biopharma to $19 From $12, Maintains Buy Rating	08/22/08	MT
Theravance Biopharma Rises After SVB Securities Initiates Outperform Rating	23/22/23	MT
SVB Securities Initiates Theravance Biopharma at Outperform With $12 Price Target	23/22/23	MT
HC Wainwright Adjusts Theravance Biopharma's Price Target to $12 From $8, Reiterates Buy Rating	24/22/24	MT
JPMorgan Upgrades Theravance Biopharma to Neutral From Underweight, Lifts Price Target to $12 From $7	05/21/05	MT
THERAVANCE BIOPHARMA : Needham Downgrades Theravance Biopharma to Hold From Buy	16/21/16	MT
THERAVANCE BIOPHARMA : Baird Adjusts Theravance Biopharma PT to $7 From $10, Maintains Neutral Rating	16/21/16	MT
THERAVANCE BIOPHARMA : Morgan Stanley Adjusts Theravance Biopharma's Price Target to $10 from $14, Keeps Underweight Rating	16/21/16	MT
THERAVANCE BIOPHARMA : SVB Leerink Cuts Price Target on Theravance Biopharma to $10 From $29, Keeps Outperform Rating	16/21/16	MT
THERAVANCE BIOPHARMA : HC Wainwright Slashes Price Target on Theravance Biopharma to $8 From $21, Keeps Buy Rating	16/21/16	MT
ANALYST RECOMMENDATIONS : Activision Blizzard, Beyond Meat, Britvic, Las Vegas Sans, Unilever...	16/21/16
THERAVANCE BIOPHARMA : JPMorgan Downgrades Theravance Biopharma to Underweight From Overweight, Adjusts Price Target to $7 From $17	15/21/15	MT
ANALYST RECOMMENDATONS : Asos, Beazley, Factset, Hiscox, Next...	25/21/25
THERAVANCE BIOPHARMA : Morgan Stanley Downgrades Theravance Biopharma to Underweight From Overweight, Lowers PT to $14 From $27	25/21/25	MT
THERAVANCE BIOPHARMA : Evercore ISI Adjusts Theravance Biopharma PT to $21 From $30, Maintains Outperform Rating	24/21/24	MT
THERAVANCE BIOPHARMA : JPMorgan Adjusts Theravance Biopharma's Price Target to $23 From $27, Maintains Overweight Rating	24/21/24	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Theravance Biopharma, Inc.

Equities

TBPH

KYG8807B1068

Analyst Reco.

Filters